Welcome to our dedicated page for CorMedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CorMedix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CorMedix's regulatory disclosures and financial reporting.
On 8 Aug 2025, individual investor Shaibatalhamd Aymen Abdalkader filed Amendment No. 2 to Schedule 13G, revealing a passive ownership position in CorMedix Inc. (CRMD).
- Shares owned: 4,645,630 common shares.
- Ownership percentage: 6.22 % of CorMedix’s outstanding stock, exceeding the 5 % disclosure threshold.
- Control rights: Sole voting and sole dispositive power over all reported shares; no shared control.
- Intent: Filer certifies the stake is not intended to influence or change control of the issuer.
No purchase prices, transaction dates, or financing details were disclosed. While the filing signals meaningful individual interest in CRMD, it conveys a passive stance and does not, by itself, indicate imminent strategic or governance changes.
CorMedix (CRMD) delivered its first profitable quarter since commercial launch of DefenCath. Q2-25 net sales surged to $39.7 m from $0.8 m a year ago, lifting H1 revenue to $78.8 m. Gross margin was 95% and operating income reached $19.5 m versus a $15.3 m loss in Q2-24; H1 operating income was $39.7 m. Net income came in at $19.8 m (-dil. EPS $0.28) for the quarter and $40.5 m for six months, despite a $2.0 m negative adjustment to Medicaid rebate estimates.
Liquidity strengthened sharply: cash and equivalents rose to $159.3 m and short-term investments to $31.4 m, driven by a $82.4 m June equity offering, $6.8 m ATM sales and $1.5 m option exercises. Stockholders’ equity climbed to $220.6 m from $84.7 m year-end.
Customer concentration remains high (Customer A 59% of Q2 sales; 45% of receivables). Gross-to-net deductions totalled $41.3 m YTD (52% of gross sales).
Strategic moves: • August 2025 agreement to acquire Melinta Therapeutics for $260 m cash + $40 m shares; closing expected Sept-25. • Parallel $150 m 4.0% senior convertible notes due 2030 to partly fund the deal. • OBBBA tax law change (July-25) expected to lower future cash taxes.
Balance sheet shows no long-term debt yet; pro-forma leverage will rise post-note issuance. Litigation (securities & derivative) continues, discovery stage.
CorMedix Inc. (Nasdaq: CRMD) has launched a follow-on equity offering under its shelf registration statement, filing a Rule 424(b)(5) prospectus supplement dated June 26 2025. The company is issuing 6,604,507 shares of common stock, with sole book-runner RBC Capital Markets purchasing the shares at $12.641 per share. This represents a 15.6% discount to the June 25 2025 closing price of $14.97. Gross proceeds to CorMedix are expected to be approximately $83.5 million before offering expenses.
The underwriters have a 30-day option to buy up to an additional 990,676 shares, which, if fully exercised, would increase the total raise to roughly $96 million. Shares are expected to be delivered on or about June 30 2025.
The prospectus highlights numerous risk factors, including: sustained operating losses, reliance on a single commercial product (DefenCath), dependence on third-party reimbursement, significant customer concentration, and the need for future financings that could be dilutive or on unfavorable terms. The document expressly cautions that forward-looking statements are subject to uncertainty and that past information may not reflect current conditions.
Key transactional terms
- Offering size: 6.60 million shares
- Offer price to underwriters: $12.641 per share
- Gross proceeds: ~$83.5 million (excluding option)
- Over-allotment option: 990,676 shares (30 days)
- Expected closing: June 30 2025
No specific use-of-proceeds breakdown is provided in the excerpt; investors are directed to the “Use of Proceeds” section (page S-6) for details. The filing reiterates that neither the SEC nor state regulators have approved or disapproved the securities and that investing involves substantial risk.
CorMedix Inc. (Nasdaq: CRMD) has filed a preliminary prospectus supplement under Rule 424(b)(5) for a common-stock offering of up to US$85 million. The company has not yet disclosed the number of shares or the final offering price, but the last reported market price on 25 June 2025 was $14.97 per share. RBC Capital Markets is the sole book-running manager, and the underwriters hold a 30-day option to purchase additional shares. The shares will be offered on Nasdaq or through negotiated transactions at prevailing or negotiated prices.
The filing forms part of CorMedix’s shelf registration statement dated 22 May 2024. Key sections include Use of Proceeds (S-6), Dilution (S-7) and Underwriting (S-10). Although precise use of proceeds is not specified in this preliminary document, management cites a continued need to finance operations and commercial expansion.
Risk highlights listed on pages S-4 onward emphasise: (i) a history of operating losses and the possibility of never achieving sustained profitability; (ii) heavy reliance on a single approved product, DefenCath®, with concentrated customers and reimbursement uncertainties; (iii) potential dilution and unfavourable terms from future financings; and (iv) regulatory and commercialisation uncertainties for pipeline products.
Investors are advised to review the full prospectus supplement, incorporated documents and forward-looking statements for detailed risk disclosures before committing capital.
CorMedix (NASDAQ:CRMD) held its 2025 Annual Meeting of Stockholders on June 24, 2025. Shareholders voted on three key proposals: election of seven directors, advisory vote on executive compensation, and ratification of the independent auditor.
All seven director nominees were successfully elected with Joseph Todisco receiving the highest approval (18.3M votes). The non-binding advisory vote on executive compensation passed with 16.1M votes in favor. Shareholders also approved CBIZ CPAs P.C. as the independent auditor with 45.5M votes in favor.
On 23 June 2025, CorMedix Inc. (CRMD) filed a Form 8-K under Item 7.01 (Regulation FD). The company disclosed that it had released a press release (attached as Exhibit 99.1) providing an update on its Large Dialysis Organization (LDO) customer and confirmed that implementation is planned for the second half of 2025. No financial metrics, contractual terms, or quantitative guidance were included in the filing. Because the information is being furnished, not filed, it is exempt from Section 18 liability and will not be automatically incorporated into other SEC filings unless specifically referenced.